Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
OMKAR PHARMACHEM ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
OMKAR PHARMACHEM Mar-23 |
ADCOCK INGRAM Jun-14 |
OMKAR PHARMACHEM/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 25 | 315 | - | |
Low | Rs | 19 | 228 | - | |
Sales per share (Unadj.) | Rs | 0.5 | 93.8 | - | |
Earnings per share (Unadj.) | Rs | 0.2 | -23.6 | - | |
Cash flow per share (Unadj.) | Rs | 0.2 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 9.0 | 73.6 | - | |
Shares outstanding (eoy) | m | 10.08 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 41.4 | 2.9 | 1,431.3% | |
Avg P/E ratio | x | 113.1 | -11.5 | -984.9% | |
P/CF ratio (eoy) | x | 111.5 | -13.9 | -805.0% | |
Price / Book Value ratio | x | 2.5 | 3.7 | 67.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 224 | 45,814 | 0.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 1 | 2,875 | 0.0% | |
Avg. sales/employee | Rs Th | 0 | 3,688.3 | - | |
Avg. wages/employee | Rs Th | 0 | 669.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -929.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5 | 15,834 | 0.0% | |
Other income | Rs m | 0 | 111 | 0.0% | |
Total revenues | Rs m | 5 | 15,945 | 0.0% | |
Gross profit | Rs m | 3 | -2,744 | -0.1% | |
Depreciation | Rs m | 0 | 683 | 0.0% | |
Interest | Rs m | 0 | 429 | 0.1% | |
Profit before tax | Rs m | 3 | -3,745 | -0.1% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1 | 234 | 0.3% | |
Profit after tax | Rs m | 2 | -3,990 | -0.0% | |
Gross profit margin | % | 57.6 | -17.3 | -332.3% | |
Effective tax rate | % | 25.2 | -6.2 | -402.8% | |
Net profit margin | % | 36.6 | -25.2 | -145.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3 | 11,597 | 0.0% | |
Current liabilities | Rs m | 7 | 6,525 | 0.1% | |
Net working cap to sales | % | -78.5 | 32.0 | -245.1% | |
Current ratio | x | 0.4 | 1.8 | 21.5% | |
Inventory Days | Days | 6,286 | 111 | 5,668.1% | |
Debtors Days | Days | 876 | 124 | 706.8% | |
Net fixed assets | Rs m | 93 | 6,760 | 1.4% | |
Share capital | Rs m | 101 | 74 | 137.2% | |
Net worth | Rs m | 90 | 12,428 | 0.7% | |
Long term debt | Rs m | 0 | 4,367 | 0.0% | |
Total assets | Rs m | 96 | 23,477 | 0.4% | |
Interest coverage | x | 6.6 | -7.7 | -85.6% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.1 | 0.7 | 8.4% | |
Return on assets | % | 2.6 | -15.2 | -16.9% | |
Return on equity | % | 2.2 | -32.1 | -6.8% | |
Return on capital | % | 3.4 | -19.8 | -17.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3 | 1,352 | 0.2% | |
From Investments | Rs m | NA | -415 | -0.0% | |
From Financial Activity | Rs m | -4 | 3,964 | -0.1% | |
Net Cashflow | Rs m | -1 | 4,900 | -0.0% |
Compare OMKAR PHARMACHEM With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare OMKAR PHARMACHEM With: PANACEA BIOTECH JAGSON PHAR DIVIS LABORATORIES MANGALAM DRUGS SYNCOM FORMULATIONS
Indian share markets continued the momentum as the session progressed and ended the higher.